Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results

TheFly reported connected January 8 that Truist raised its terms people connected BBIO to $86 from $80 portion maintaining a Buy rating. The steadfast updated its exemplary but noted successful a probe enactment that its cardinal views stay unchanged from 2025.

In keeping with this affirmative view, connected January 12, BridgeBio Pharma, Inc. (NASDAQ:BBIO) gave a important operational update astatine the 44th Annual J.P. Morgan Healthcare Conference. For Attruby, the steadfast announced preliminary unaudited revenues of $146.0 cardinal for the 4th fourth of 2025, totaling $362.4 cardinal successful merchandise gross for the afloat twelvemonth of 2025. This accomplishment amply illustrates the accelerated marketplace adoption of Attruby arsenic a first-choice attraction for recently diagnosed ATTR-CM patients, with implicit 6,000 unsocial prescriptions written by the extremity of 2025.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) develops therapies for familial diseases and cancers, supporting its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT), which advances precision crab treatments targeting cardinal oncogenes similar RAS and PI3K into objective trials.

While we admit the imaginable of BBIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.